Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine k...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ting-Ting, Chen, Wei-Hao, Zhao, Yan-Min, Fu, Hua-Rui, Huang, He, Shi, Ji-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117139/
https://www.ncbi.nlm.nih.gov/pubmed/33996600
http://dx.doi.org/10.3389/fonc.2021.672052
_version_ 1783691541720596480
author Yang, Ting-Ting
Chen, Wei-Hao
Zhao, Yan-Min
Fu, Hua-Rui
Huang, He
Shi, Ji-Min
author_facet Yang, Ting-Ting
Chen, Wei-Hao
Zhao, Yan-Min
Fu, Hua-Rui
Huang, He
Shi, Ji-Min
author_sort Yang, Ting-Ting
collection PubMed
description Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor. Our report supports the efficacy of bruton tyrosine kinase inhibitor zanubrutinib in the treatment of CNS-PTLD, which provides a new therapeutic option.
format Online
Article
Text
id pubmed-8117139
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81171392021-05-14 Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report Yang, Ting-Ting Chen, Wei-Hao Zhao, Yan-Min Fu, Hua-Rui Huang, He Shi, Ji-Min Front Oncol Oncology Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor. Our report supports the efficacy of bruton tyrosine kinase inhibitor zanubrutinib in the treatment of CNS-PTLD, which provides a new therapeutic option. Frontiers Media S.A. 2021-04-29 /pmc/articles/PMC8117139/ /pubmed/33996600 http://dx.doi.org/10.3389/fonc.2021.672052 Text en Copyright © 2021 Yang, Chen, Zhao, Fu, Huang and Shi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Ting-Ting
Chen, Wei-Hao
Zhao, Yan-Min
Fu, Hua-Rui
Huang, He
Shi, Ji-Min
Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title_full Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title_fullStr Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title_full_unstemmed Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title_short Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
title_sort zanubrutinib treatment of central nervous system posttransplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117139/
https://www.ncbi.nlm.nih.gov/pubmed/33996600
http://dx.doi.org/10.3389/fonc.2021.672052
work_keys_str_mv AT yangtingting zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT chenweihao zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT zhaoyanmin zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT fuhuarui zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT huanghe zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport
AT shijimin zanubrutinibtreatmentofcentralnervoussystemposttransplantlymphoproliferativedisorderafterallogeneichematopoieticstemcelltransplantationacasereport

Ejemplares similares